Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma

NCT00450593 | Unknown

• 3 other identifiers: CRUK-LCC-99/3/45CDR0000532941EU-20705
• Study Type: observational
• Target: 5,000
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer. It may also help the study of cancer in the future. PURPOSE: This clinical trial is studying gene mutations in patients with melanoma and in families with a history of hereditary melanoma.

Conditions

Hereditary Multiple Melanoma; Melanoma (Skin)

Keywords

melanoma; hereditary multiple melanoma; recurrent melanoma; stage 0 melanoma; stage IV melanoma; stage IA melanoma; stage IB melanoma; stage IIA melanoma; stage IIB melanoma; stage IIC melanoma; stage IIIA melanoma; stage IIIB melanoma; stage IIIC melanoma

Outcome Measures

Primary Outcomes (4)

• Predictive significance of melanoma susceptibility gene (MSG) mutations in the CDKN2A gene

• Susceptibility to other types of cancer as a feature of MSG mutations

• Risk of other types of cancers in mutation carriers

• Environmental exposures, in particular sun exposure, that modify risk of melanoma in MSG mutation carriers

Interventions

gene expression analysis GENETIC

microarray analysis GENETIC

molecular genetic technique GENETIC

mutation analysis GENETIC

laboratory biomarker analysis OTHER

mutation carrier screening PROCEDURE

study of high risk factors PROCEDURE

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Meets one of the following criteria: * Prior multiple primary melanomas * Histological samples available * Family history of melanoma, with melanoma in two first-degree relatives (e.g., cases of melanoma in both a mother and son or in two brothers but not in two cousins) * Family history of melanoma, where three or more individuals (of any relationship) have had melanoma PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Leeds Cancer Centre at St. James's University Hospital: lead

Study Sites (1)

Leeds Cancer Centre at St. James's University Hospital

Leeds, England, LS9 7TF, United Kingdom

RECRUITING

MeSH Terms

Conditions

Melanoma, Cutaneous Malignant; Melanoma

Interventions

Gene Expression Profiling; Microarray Analysis; Genetic Testing

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Genetic Techniques; Investigative Techniques; Microchip Analytical Procedures; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Genetic Services; Health Services; Health Care Facilities Workforce and Services; Diagnostic Services; Preventive Health Services

Study Officials

• Julia Newton Bishop, MD

  Leeds Cancer Centre at St. James's University Hospital

  STUDY CHAIR

Study Design

• Study Type: observational
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: March 20, 2007
• First Posted: March 22, 2007
• Study Start: January 1, 1989
• Primary Completion: December 1, 2020
• Last Updated: August 12, 2013

Record last verified: 2008-04

Locations

GB (1)